CD8A and neoplasm: It is worth noting that the single-regimen treatment like anti-PD-1 antibodies or CBDCA did not change the percentage of memory CD8+ T cells in the tumor at this time point and that the combination therapy significantly increased the abundance of memory CD8+ T cells compared to treatment with CBDCA or anti-PD-1 (Figure 4C), indicating the possible tumor killing effects executed by memory CD8+ T cells.